HNF and Acceleron Pharma have been collaborating since January, 2016. Acceleron Pharma is a ”clinical stage biopharmaceutical company.”
HNF presenting and attending prestigious conferences worldwide.
HNF launches GRIN with 4 online clinical studies that are important as we continue with our therapy development pipelines.
2018 was a pivotal year for the Hereditary Neuropathy Foundation (HNF) and the entire Charcot-MarieTooth (CMT) Community.
True Reply’s Voice Activated Technology is an accessible and innovative new platform that captures the patient’s experience with CMT in their own words.
Help us to improve outcome measures, develop biomarkers and improve patient care by joining the Global Registry for Inherited Neuropathies
There are those situations in life where you are destined to meet and for me, meeting Dr. Jahannaz Dastgir — “Naz for short” — was one of them.
HNF would like to announce, with great pleasure, that it has been invited to participate in the Inherited Neuropathy Consortium (INC), one of 22 groups under the Rare Diseases Clinical Research Network.
Cannabis Community Care & Research Network (C3RN) is excited to be partnering with HNF to advance Cannabis research, advocate for patients in need, and educate the community!
The Annual RARE Patient Advocacy Summit, hosted by Global Genes, is in its seventh year and will take place on October 3-4 at the Hotel Irvine in Irvine, California.
On May 19, HNF participated in the Rare Patient Advocacy Symposium in partnership with Penn Medicine Orphan Disease Center and Global Genes.
The 2018 Rare Neurological Disease Special Report has been published by Neurology Reviews in collaboration with NORD.